Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Tempus AI, Inc. - Class A Common Stock (NQ:TEM)

49.16 +0.75 (+1.55%)

Streaming Delayed Price Updated: 1:29 PM EDT, Jul 21, 2026 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	2,913,002
Open	48.52
Bid (Size)	49.13 (100)
Ask (Size)	49.17 (400)
Prev. Close	48.41
Today's Range	47.74 - 50.01
52wk Range	41.73 - 104.32
Shares Outstanding	N/A
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Tempus AI Bets on MRD Testing Growth With Personalis Acquisition ↗

July 20, 2026

Tempus AI (NASDAQ:TEM) executives said the company’s planned acquisition of Personalis is intended to strengthen its position in minimal residual disease, or MRD, testing, while expanding its biopharma...

Via MarketBeat

Tempus Highlights Landmark Publication Demonstrating Safe, Real-World Deployment of Paige Prostate AI Suite in the UK National Health Service

July 16, 2026

From Tempus

Via Business Wire

Performance

YTD	-21.2%	-21.2%
1 Month	+2.7%	+2.7%
3 Month	-13.4%	-13.4%
6 Month	-26.4%	-26.4%
1 Year	-15.3%	-15.3%

More News

Tempus to Report Second Quarter 2026 Financial Results on July 30

July 09, 2026

From Tempus AI, Inc.

Via Business Wire

Tempus Announces Research Collaboration with Angiosarcoma Awareness, Inc. to Uncover Insights on Rare Cancers

June 25, 2026

From Tempus AI, Inc.

Via Business Wire

Tempus Announces Multi-Center Validation of AI-Enabled ECG Model for Predicting Atrial Fibrillation Risk Published in Heart Rhythm

June 11, 2026

From Tempus AI, Inc.

Via Business Wire

Genetics in Medicine Open Study Demonstrates How Ambry Genetics’ ExomeReveal® RNA Testing Can Improve Diagnostic Clarity in Exome Testing

June 09, 2026

From Ambry Genetics

Via Business Wire

Great News: This Explosive Healthcare Stock Could Be a Powerful Artificial Intelligence Winner ↗

June 08, 2026

Via The Motley Fool

Tempus to Present at the Goldman Sachs 47th Annual Global Healthcare Conference

June 05, 2026

From Tempus AI, Inc.

Via Business Wire

Why Tempus AI Stock Is Surging On Thursday? ↗

June 04, 2026

Via Benzinga

Tempus Launches Open-Source Digital Pathology Consortium, Names Yale New Haven Health and Leading Cancer Center as Founding Members

June 03, 2026

From Tempus AI, Inc.

Via Business Wire

Tempus Announces the Upcoming Clinical Availability of Its First Whole-Genome Sequencing Assay, xH

June 01, 2026

From Tempus AI, Inc.

Via Business Wire

Tempus Unveils the Next-Generation of Lens, Expanding its Agentic AI Platform for Oncology Drug Development

May 31, 2026

From Tempus AI, Inc.

Via Business Wire

What to Know About This Fund's $32.6 Million Porch Group Purchase ↗

May 30, 2026

Via The Motley Fool

Tempus Launches the PRECISION Challenge, a National Program Opening Its Foundation Model Work to the Broader Research Community

May 30, 2026

From Tempus AI, Inc.

Via Business Wire

Tempus Introduces ‘Preview’: Bridging the Critical Time Gap Between Diagnostic Order and Definitive Results

May 30, 2026

From Tempus AI, Inc.

Via Business Wire

Tempus Announces Initial Results from its Multimodal Foundation Model Efforts for Novel and Scalable Insight Generation in Oncology

May 29, 2026

From Tempus AI, Inc.

Via Business Wire

Tempus Receives FDA Approval for Tumor Only xT CDx, Enabling Migration of its Entire DNA Solid Tumor Portfolio

May 29, 2026

From Tempus AI, Inc.

Via Business Wire

Why Is Tempus AI Stock Surging On Thursday? ↗

May 28, 2026

Via Benzinga

Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought ↗

May 28, 2026

Via The Motley Fool

Tempus Expands Next Platform to Deliver Real-Time Clinical Intelligence and Close Critical Care Gaps Across Oncology

May 28, 2026

From Tempus AI, Inc.

Via Business Wire

Tempus Upgrades Its Smart Physician Platform, Hub, with Next-Generation Agentic AI Architecture to Streamline Clinical Workflows

May 27, 2026

From Tempus AI, Inc.

Via Business Wire

Tempus Announces 37 Abstracts Accepted for Presentation at the 2026 American Society of Clinical Oncology Annual Meeting

May 26, 2026

From Tempus AI, Inc.

Via Business Wire

Tempus Launches ArteraAI Prostate Test for Metastatic Patients, Marking the First Prostate Digital Pathology Algorithm in the Tempus Ecosystem Available for Clinical Use

May 21, 2026

From Tempus AI, Inc.

Via Business Wire

Tempus Expands Strategic Collaboration with Bristol Myers Squibb to Enhance the Probability of Success Across Clinical Development Programs In Oncology and Neuroscience

May 14, 2026

From Tempus AI, Inc.

Via Business Wire

TechMediaBreaks – MindBio Therapeutics Corp. (CSE: MBIO; Frankfurt: WF6; OTCQB: MBQIF) Advances AI Voice-Based Intoxication Detection as Real-Time Diagnostics Market Expands

May 11, 2026

Via Investor Brand Network

Frequently Asked Questions

Is Tempus AI, Inc. - Class A Common Stock publicly traded?

Yes, Tempus AI, Inc. - Class A Common Stock is publicly traded.

What exchange does Tempus AI, Inc. - Class A Common Stock trade on?

Tempus AI, Inc. - Class A Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Tempus AI, Inc. - Class A Common Stock?

The ticker symbol for Tempus AI, Inc. - Class A Common Stock is TEM on the Nasdaq Stock Market

What is the current price of Tempus AI, Inc. - Class A Common Stock?

The current price of Tempus AI, Inc. - Class A Common Stock is 49.16

When was Tempus AI, Inc. - Class A Common Stock last traded?

The last trade of Tempus AI, Inc. - Class A Common Stock was at 07/21/26 01:29 PM ET

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.